Northwire Canada EditionThursday, July 23, 2026
Sign inSubscribe
Northwire
⌕
TECK 83.44 +3.5% FVI 11.85 −2.1% SUM 1.31 −1.5% RSMX 0.105 −4.5% STW 0.105 +5.0% PAT 0.250 +0.0% CCM 0.530 +1.9% SGN 0.250 −2.0% CNC 1.48 +0.7% PHNM 0.340 +4.6% LIO 0.160 +0.0% RIO 2.67 −4.5% KG 0.160 +3.2% GEN 0.065 +0.0% ECU 1.64 +8.6% ALTA 0.170 −2.9% TECK 83.44 +3.5% FVI 11.85 −2.1% SUM 1.31 −1.5% RSMX 0.105 −4.5% STW 0.105 +5.0% PAT 0.250 +0.0% CCM 0.530 +1.9% SGN 0.250 −2.0% CNC 1.48 +0.7% PHNM 0.340 +4.6% LIO 0.160 +0.0% RIO 2.67 −4.5% KG 0.160 +3.2% GEN 0.065 +0.0% ECU 1.64 +8.6% ALTA 0.170 −2.9%

← Back to our analysis

Original News Release

Briacell selected for MSK's Therapeutics Accelerator

Briacell Therapeutics Corp Aug 13, 2025 · 17:08 BCT As distributed — unedited
Dr. William Williams reports BRIACELL SELECTED FOR MSK'S 2025 THERAPEUTICS ACCELERATOR PROGRAM FOR BRIA-OTS+™ FOR CANCER Briacell Therapeutics Corp. has been accepted into Memorial Sloan Kettering Cancer Center's (MSK's) Therapeutics Accelerator 2025 Cohort program. This project aims to accelerate the clinical development of Bria-OTS+, Briacell's next-generation personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer, prostate cancer and other cancers. As one of the world's foremost cancer research and treatment institutions, MSK has more than 135 years of leadership in patient care, education and discovery. Through the MSK Therapeutics Accelerator Cohort program, Briacell will explore access to MSK's expertise and institutional resources, including GMP manufacturing services, investigational new drug (IND) application preparation, and submission and regulatory strategy support to expedite Bria-OTS+ development. "We are honoured to work with the scientific and clinical experts at MSK Therapeutics Accelerator," stated Dr. William V. Williams, Briacell's president and chief executive officer. "MSK's deep expertise in cancer therapy development and state-of-the-art resources make it an ideal partner to accelerate our personalized off-the-shelf immunotherapy platform." "We are excited to welcome Briacell into the cohort program," stated Eileen Flowers, PhD, director, technology development and licensing, in the office of entrepreneurship and commercialization at MSK. "We believe Bria-OTS+ has the potential to transform cancer care, offering meaningful advances in efficacy and safety for thousands of patients," stated Dr. Miguel Lopez-Lago, Briacell's chief scientific officer. "Our participation in this cohort program is yet another step towards achieving that vision." About Briacell Therapeutics Corp. Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. We seek Safe Harbor.
View at source ↗